Francois Cherifi

Caen, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 32 publications

Characteristics, treatment and survival of older patients with metastatic triple negative breast cancer from the ESME mBC real-world national cohort: a comparison with younger women.

Characteristics, treatment and survival of older patients with metastatic triple negative breast cancer from the ESME mBC real-world national cohort: a comparison with younger women.

Journal: Breast (Edinburgh, Scotland)

Published: February 17, 2026

Hematological immune-related adverse events associated with checkpoint inhibitors.

Hematological immune-related adverse events associated with checkpoint inhibitors.

Journal: Cancer treatment reviews

Published: January 21, 2026

Ischaemic stroke and 5-fluorouracil or capecitabine: A systematic review and meta-analysis of harms and a retrospective study of the WHO pharmacovigilance database.

Ischaemic stroke and 5-fluorouracil or capecitabine: A systematic review and meta-analysis of harms and a retrospective study of the WHO pharmacovigilance database.

Journal: British journal of pharmacology

Published: November 05, 2025

Return to work among self-employed breast cancer survivors from the CANTO cohort.

Return to work among self-employed breast cancer survivors from the CANTO cohort.

Journal: Scientific reports

Published: October 23, 2025

Activity of Platinum Monotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer and DNA Damage Repair Gene Alterations.

Activity of Platinum Monotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer and DNA Damage Repair Gene Alterations.

Journal: JCO precision oncology

Published: August 07, 2025

Association between molecular classification and overall survival in patients with metastatic endometrial carcinoma: ancillary results of the UTOLA phase II GINECO trial.

Association between molecular classification and overall survival in patients with metastatic endometrial carcinoma: ancillary results of the UTOLA phase II GINECO trial.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: August 04, 2025

PROMENADE: pembrolizumab for early ER-low/HER2-negative breast cancer, real-world French cohort.

PROMENADE: pembrolizumab for early ER-low/HER2-negative breast cancer, real-world French cohort.

Journal: ESMO open

Published: July 08, 2025

Homologous recombination deficiency (HRD) tests for ovarian cancer: a multicenter French phase II study (HERO).

Homologous recombination deficiency (HRD) tests for ovarian cancer: a multicenter French phase II study (HERO).

Journal: BMC cancer

Published: May 22, 2025

DOMENICA: dostarlimab versus chemotherapy alone in first-line MMR-deficient advanced endometrial cancer patients.

DOMENICA: dostarlimab versus chemotherapy alone in first-line MMR-deficient advanced endometrial cancer patients.

Journal: Future oncology (London, England)

Published: May 05, 2025

Risk models of cancer-related cognitive complaints among early breast cancer survivors in the CANTO cohort.

Risk models of cancer-related cognitive complaints among early breast cancer survivors in the CANTO cohort.

Journal: Journal of the National Cancer Institute

Published: April 15, 2025

Aromatase Inhibitor-Induced Arthralgia Among Patients With Early Breast Cancer: Prevalence, Treatment Nonadherence, and Management in a Prospective Longitudinal Cohort.

Aromatase Inhibitor-Induced Arthralgia Among Patients With Early Breast Cancer: Prevalence, Treatment Nonadherence, and Management in a Prospective Longitudinal Cohort.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: April 15, 2025

The PENDOR study: establishment of a panel of patient-derived tumor organoids from endometrial cancer to assess efficacy of PARP inhibitors.

The PENDOR study: establishment of a panel of patient-derived tumor organoids from endometrial cancer to assess efficacy of PARP inhibitors.

Journal: BMC cancer

Published: December 20, 2024

Showing 1-12 of 32

Last Updated: 09/26/2026